Tag Archives: GSK
By Guest Blogger | Published: January 4, 2012
Big Pharma received a nod in the UK’s New Year’s Honours List this week when a knighthood was duly bestowed upon GSK’s Andrew Witty — making him ‘Sir Andrew’ to you and me. For once, though, receiving such an honor did not exactly place him in totally exalted company.
By William Looney | Published: October 19, 2011
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty. If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what […]
By Guest Blogger | Published: June 29, 2011
Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
By William Looney | Published: April 19, 2011
Pharm Exec’s sister conferencing unit explores the future of the US sales rep, including the implications of GSK’s new value-based compensation model Last week brought a small but dedicated group of sales professionals to a CBI conference in San Diego with a clear mandate: to rate the future of the “detail man” — dead or […]
By admin | Published: November 17, 2010
Former GSK counsel is the first target in government’s executive-liability crackdown. Could J&J be next? The US Department of Justice filed criminal charges last week against Lauren Stevens, a former VP and assistant general counsel at GlaxoSmithKline. Going after pharma execs marks a seismic shift in the government’s efforts to stem the tide of fraud […]